首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1471974

基因治療市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按載體、適應症、交付模式和地理位置

Gene Therapy Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Vectors, Indication, Delivery Mode, and Geography

出版日期: 2024年03月13日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

基因治療市場規模預計將從2023年的51.1億美元成長到2031年的256.9億美元；預計 2023 年至 2031 年複合年成長率為 14.3%。

基因療法是利用基因治療疾病的開創性治療方法。基因療法透過將遺傳物質引入患者的細胞來替換或糾正異常基因，為治療和治癒疾病提供了一種有前途的方法。基因治療可分為體內基因治療及離體基因治療。這種創新的治療方法近年來獲得了極大的關注和投資，導致基因治療技術和技術的進步。基因治療市場的成長歸因於遺傳疾病負擔的增加以及 FDA 批准基因治療的數量不斷增加。然而，基因治療產品的高成本阻礙了基因治療市場的成長。

研究人員正在致力於將基因療法應用於臨床。各大學和研究所正在開發各種產品組合，預計在預測期內創造收入將會增加。在FDA 批准第一個基因療法後，基因療法的臨床試驗數量從2017 年到2018 年急劇增加。。在預測期內，預計強勁的產品線將為基因治療市場的成長提供新的機會。

基於向量的見解

根據載體，基因治療市場分為非病毒載體和病毒載體。到 2023 年，病毒載體細分市場將佔據重要的基因治療市場。病毒載體能夠將遺傳物質有效地遞送至目標細胞。它們源自於自然可以感染細胞並轉移其遺傳物質的病毒。這使得它們能夠非常有效地將治療基因傳遞到患者的細胞中。此外，病毒載體具有高水準的特異性和選擇性。它們可以被設計為針對特定類型的細胞或組織，從而實現治療基因的標靶遞送。這在基因治療中尤其重要，因為它降低了脫靶效應的風險並提高了治療的有效性。此外，多年來，病毒載體經過廣泛的研究和最佳化，導致了更安全、更有效的載體系統的開發。載體設計和製造技術的進步提高了病毒載體的安全性和可擴展性，使其更適合臨床應用。

根據 ClinicalTrials.gov 的分析，約 58% 正在開發的基因療法使用病毒載體。用於基因治療的最常用病毒載體是腺相關病毒，因為它能夠將基因遞送至非分裂細胞，在非分裂細胞中該基因具有長期治療作用。不同種類的腺相關病毒針對不同的細胞，使它們成為遺傳物質到體內所需位置的合適轉運體，從而提供客製化的治療。此外，病毒載體表現出低免疫原性、安全性和長期瞬時表達。總體而言，對安全有效的基因治療的需求不斷成長，加上病毒載體提供的優勢，促進了該領域的顯著成長，對基因治療市場的成長產生了積極影響。

美國食品藥物管理局、世界衛生組織和疾病管制與預防中心是準備基因療法市場報告時參考的主要和次要來源之一。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：基因治療市場 - 主要公司概況

Novartis AG
Astellas Pharma Inc
Bristol-Myers Squibb Company
Bluebird Bio Inc.
Sanofi
F. Hoffmann-La Roche Ltd.
Daiichi Sankyo
CSL Behring
Biogen
Oxford Biomedica

第 14 章：附錄

簡介目錄

Product Code: TIPHE100001165

The gene therapy market size is expected to grow from US$ 5.11 billion in 2023 to US$ 25.69 billion by 2031; it is projected to register a CAGR of 14.3% during 2023-2031.

Gene therapy is a pioneering treatment method that uses genes to treat diseases. Gene therapy offers a promising approach to treat and cure diseases by introducing genetic material into a patient's cells to replace or correct abnormal genes. Gene therapy can be classified into in-vivo and ex-vivo gene therapy. This innovative treatment method has gained significant attention and investment in recent years, leading to advancements in gene therapy techniques and technologies. The gene therapy market growth is attributed to the increasing burden of genetic diseases and the rising number of FDA approvals of gene therapies. However, the high cost of gene therapy products hinders the growth of the gene therapy market.

Researchers are working on making gene therapy available in clinics. A wide range of product portfolios are in the pipeline at various universities and institutes, and revenue generation is expected to increase during the forecast period. Following the FDA's approval of the first gene therapy, the number of clinical trials for gene therapy surged dramatically from 2017 to 2018. About 1,986 products, including CAR T-cell treatments and other genetically engineered cell therapies, are currently under development, according to the American Society of Gene & Cell Therapy. Over the projection period, the robust pipeline is anticipated to offer new opportunities for the growth of the gene therapy market.

Vectors-Based Insights

Based on vectors, the gene therapy market is categorized into non-viral vectors and viral vectors. The viral vectors segment held a significant gene therapy market share in 2023. It is anticipated to record a higher CAGR in the market during the forecast period. Viral vectors have the ability to competently deliver genetic material into target cells. They are derived from viruses that naturally can infect cells and transfer their genetic material. This makes them highly effective in delivering therapeutic genes into the cells of patients. In addition, viral vectors offer a high level of specificity and selectivity. They can be engineered to target particular types of cells or tissues, allowing for targeted delivery of therapeutic genes. This is particularly important in gene therapy, as it reduces the risk of off-target effects and enhances the effectiveness of the treatment. Moreover, viral vectors have been extensively studied and optimized over the years, leading to the development of safer and more efficient vector systems. Advances in vector design and manufacturing technologies have improved the safety profile and scalability of viral vectors, making them more suitable for clinical applications.

According to the analysis from clinicaltrials.gov, ~58% of gene therapies under development are using viral vectors. The most commonly employed viral vector for gene therapy is adeno-associated virus, owing to its ability to deliver genes to non-dividing cells where the gene has a long-term therapeutic impact. Different varieties of adeno-associated viruses target different cells, making them a suitable transporter of genetic material to desired locations inside the body, providing a customized treatment. In addition, viral vectors display low immunogenicity, safety, and long-term transient expression. Overall, the growing demand for safe and effective gene therapies, along with the advantages offered by viral vectors, has contributed to the segment's significant growth, positively influencing the gene therapy market growth.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the gene therapy market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gene Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Gene Therapy Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Gene Therapy Market - Global Market Analysis

6.1 Gene Therapy - Global Market Overview
6.2 Gene Therapy - Global Market and Forecast to 2031

7. Gene Therapy Market - Revenue Analysis (USD Million) - By Vector Type, 2021-2031

7.1 Overview
7.2 Viral Vector
7.3 Non-Viral Vector

8. Gene Therapy Market - Revenue Analysis (USD Million) - By Method, 2021-2031

8.1 Overview
8.2 Ex-Vivo
8.3 In-Vivo

9. Gene Therapy Market - Revenue Analysis (USD Million) - By Application, 2021-2031

9.1 Overview
9.2 Neurological Disorders
9.3 Cancer
9.4 Duchenne Muscular Dystrophy
9.5 Hepatological Diseases
9.6 Other Indications

10. Gene Therapy Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Gene Therapy Market Overview
- 10.1.2 North America Gene Therapy Market Revenue and Forecasts to 2031
- 10.1.3 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Vector Type
- 10.1.4 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Method
- 10.1.5 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Application
- 10.1.6 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Gene Therapy Market
    - 10.1.6.1.1 United States Gene Therapy Market, by Vector Type
    - 10.1.6.1.2 United States Gene Therapy Market, by Method
    - 10.1.6.1.3 United States Gene Therapy Market, by Application
  - 10.1.6.2 Canada Gene Therapy Market
    - 10.1.6.2.1 Canada Gene Therapy Market, by Vector Type
    - 10.1.6.2.2 Canada Gene Therapy Market, by Method
    - 10.1.6.2.3 Canada Gene Therapy Market, by Application
  - 10.1.6.3 Mexico Gene Therapy Market
    - 10.1.6.3.1 Mexico Gene Therapy Market, by Vector Type
    - 10.1.6.3.2 Mexico Gene Therapy Market, by Method
    - 10.1.6.3.3 Mexico Gene Therapy Market, by Application

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Gene Therapy Market - Key Company Profiles

13.1 Novartis AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies